Winston Laboratories, Inc. Announces Positive Top-line Results Of Phase II Clinical Trial Of Civamide Patch
Winston Laboratories, Inc. (“Winston Labs”), a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. (OTC BB: WPHM) today announced positive top-line results from Study WL1001-04-03, a Phase II clinical trial evaluating the safety and efficacy of the company’s patch formulation of Civamide, a novel TRPV-1 receptor modulator in the treatment of post-herpetic neuralgia (PHN). The study successfully demonstrated the efficacy of Civamide Patch 0.
Related Posts
Tags: civamide, clinical, laboratories, line, patch, phase, positive, results, trial, winston
This entry was posted on Wednesday, November 18th, 2009 at 6:11 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
